March 2026 — Global Biotech NewsLentiviral vector technology continues to play a central role in the evolution of CAR-T cell therapies, as researchers advance strategies aimed at delivering chimeric ...
On February 19, 2026, Japan's Ministry of Health, Labour and Welfare (MHLW) granted conditional and time-limited approval to the world's first two induced pluripotent stem cell (iPSC)–based r...
February 2026 — Global Biotech NewsShanghai, China / Global — CARsgen Therapeutics Holdings Ltd., a clinical-stage biotechnology company focused on innovative chimeric antigen receptor T-cell (CAR-T...
February 2026 — Industry NewsThe global cell and gene therapy (CGT) sector continues to expand, with recent industry data highlighting a combination of strong product revenues, increasing regulatory ...
February 2026 — Global Biotech NewsSan Francisco, CA / USA — The U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for SRN-101, an AAV-based immuno-ge...
February 2, 2026 — Global Biotech NewsSilver Spring, MD, USA — Senior officials at the U.S. Food and Drug Administration (FDA) have urged biotechnology companies to implement long-term monitoring of...
January 2026Sarepta Therapeutics announced new three-year follow-up data showing that its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) continued to demonstrat...
January 25, 2026 — Global Biotech NewsCopenhagen, Denmark / Vancouver, Canada — Danish pharmaceutical giant Novo Nordisk A/S has announced an expansion of its strategic collaboration with Canadian...
January 2026A pivotal Phase III cell therapy clinical trial evaluating a novel donor-derived dopamine-producing cell therapy has commenced enrollment across multiple countries, including Australia, Ca...
January 2026 — Industry NewsThe Asia-Pacific gene therapy market is projected to experience rapid growth over the next decade, with market size expected to reach approximately US$14.59 billion by 20...
January 13, 2026The U.S. Food and Drug Administration (FDA) has declined to approve Atara Biotherapeutics’ cell therapy tabelecleucel for the treatment of Epstein-Barr virus positive post-transplant ...
January 2026The U.S. Food and Drug Administration (FDA) has announced an updated regulatory approach aimed at increasing flexibility in the development and manufacturing oversight of cell and gene the...
86 198 5711 6962 
info@hillgene.com 
English
